Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) – Pipeline Review, H2 2017’, provides in depth analysis on Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Hematological Disorders, Genetic Disorders, Immunology and Oncology under development targeting Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)

The report reviews Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics and enlists all their major and minor projects

The report assesses Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Daiichi Sankyo Co Ltd

Pieris Pharmaceuticals Inc

Protagonist Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Overview 6

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Therapeutics Assessment 12

Assessment by Mechanism of Action 12

Assessment by Route of Administration 14

Assessment by Molecule Type 16

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Companies Involved in Therapeutics Development 18

Daiichi Sankyo Co Ltd 18

Pieris Pharmaceuticals Inc 18

Protagonist Therapeutics Inc 19

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drug Profiles 20

DS-79182026 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

Fusion Protein to Replace Hepcidin for Iron Overload Disorders - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

M-009 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

PRS-080 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

PTG-300 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Dormant Products 28

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Discontinued Products 29

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Product Development Milestones 30

Featured News & Press Releases 30

Sep 20, 2017: Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 30

Jun 04, 2017: Pieris Pharmaceuticals Announces Presentation of Clinical Data for Anemia Drug Candidate, PRS-080, at the 54th ERA-EDTA Congress 30

May 25, 2017: Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300 31

Jul 28, 2016: Protagonist Therapeutics Receives SBIR Funding for the Development of Injectable Hepcidin Mimetics for Treatment of Iron Overload Disorders 31

May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases 32

Dec 07, 2015: Pieris Pharmaceuticals Presents Clinical Data for its Hepcidin Antagonist Program, PRS-080, at the 2015 American Society Of Hematology Annual Meeting 33

Nov 05, 2015: Pieris Pharmaceuticals Announces Presentation Of Clinical Data For Its Hepcidin Antagonist Program, Prs-080, At The 2015 American Society Of Hematology Annual Meeting 33

Jun 10, 2015: Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia 34

Dec 11, 2014: Pieris Initiates Phase I Clinical Trial for Anticalin to Treat Anemia 35

Dec 13, 2011: Pieris Presents Preclinical Data For PRS-080 Hepcidin Antagonist Anticalin Program At ASH Annual Meeting 35

May 23, 2011: Pieris Announces Preclinical In Vitro And In Vivo Data For Anticalin PRS-080 Hepcidin Antagonist Drug Program 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 13

Number of Products by Stage and Route of Administration, H2 2017 15

Number of Products by Stage and Molecule Type, H2 2017 17

Pipeline by Daiichi Sankyo Co Ltd, H2 2017 18

Pipeline by Pieris Pharmaceuticals Inc, H2 2017 19

Pipeline by Protagonist Therapeutics Inc, H2 2017 19

Dormant Projects, H2 2017 28

Discontinued Products, H2 2017 29

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 12

Number of Products by Stage and Mechanism of Actions, H2 2017 12

Number of Products by Routes of Administration, H2 2017 14

Number of Products by Stage and Routes of Administration, H2 2017 14

Number of Products by Molecule Types, H2 2017 16

Number of Products by Stage and Molecule Types, H2 2017 16

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports